SHERIDAN, WYOMING - May 13, 2026 - Roche has received CE Mark for Elecsys® pTau217, a blood-based diagnostic test designed to detect amyloid pathology associated with Alzheimer's disease, developed in collaboration with Eli Lilly and Company. The test measures phosphorylated Tau 217 protein from a routine blood draw and is intended to rule in or rule out amyloid pathology across both primary and secondary care settings using a single-assay design with unified cutoffs. The regulatory clearance positions Elecsys® pTau217 for deployment across Roche's installed base of laboratory instruments in CE mark-accepting countries, with potential FDA clearance in the United States under consideration for later this year.
A Diagnostic Gap That Has Persisted for Decades
The scale of unmet need in Alzheimer's diagnosis is well-documented. An estimated 75% of people living with dementia remain undiagnosed. Those who do receive a diagnosis typically wait an average of around 3.5 years after cognitive decline symptoms first appear. Alzheimer's disease is the most common cause of dementia, yet confirming its underlying pathology has historically required access to specialized, resource-intensive procedures.
Current gold-standard methods for detecting amyloid pathology - positron emission tomography (PET) scans and cerebrospinal fluid (CSF) assessments - are expensive, difficult to access in many healthcare settings and perceived as significantly more invasive than a routine blood draw. For health systems managing rising demand for cognitive decline assessment, these barriers have created a structural bottleneck between symptom onset and confirmed diagnosis.
Elecsys® pTau217 is designed to address that bottleneck directly. By converting amyloid detection into a high-throughput, automated blood test compatible with standard laboratory workflows, Roche is positioning the assay as a front-line triage tool for primary care clinicians who currently have limited diagnostic options before specialist referral.
Single-Assay Design With Unified Cutoffs Across Care Settings
The clinical architecture of Elecsys® pTau217 is built around operational simplicity. A single set of cutoffs - high and low - applies across both primary and secondary care, eliminating the need for setting-specific recalibration. A positive result indicates a high likelihood of amyloid pathology and can guide clinicians toward timely specialist referral or further evaluation. A negative result indicates a low likelihood, enabling clinicians to consider alternative causes of cognitive symptoms and avoid unnecessary invasive procedures.
An indeterminate result requires additional testing. The assay is intended to be used in conjunction with other clinical information rather than as a standalone diagnostic instrument. Within those parameters, the test is designed to support flexible laboratory workflows and sample handling procedures consistent with routine diagnostic processes.
For laboratory operators and clinical procurement teams, the assay's compatibility with Roche's large installed instrument base is a critical implementation detail. Deployment does not require new capital equipment in facilities already operating Roche diagnostic platforms, reducing the infrastructure barrier to adoption.
CE Mark Based on Real-World Population Data at Earliest Disease Stages
The CE Mark was granted on the basis of data from retrospective studies conducted in a real-world population at the earliest stages of Alzheimer's progression - covering Subjective Cognitive Decline, Mild Cognitive Impairment and Mild Dementia. This is the patient population where individuals may notice memory changes but remain largely independent.
Validating performance at this stage of the disease is clinically significant. It is precisely the point where timely intervention has the greatest potential to slow progression, preserve function and allow patients and families to plan care pathways with meaningful lead time. Accuracy comparable to CSF diagnostics against PET-CT gold standard performance at this early stage strengthens the case for the test as a genuine front-line tool rather than a secondary confirmation instrument.
"The launch of pTau217 marks a significant step in providing a simple, blood-based tool to diagnose Alzheimer's much earlier in the patient journey. Today, many people face a long and difficult path to a diagnosis, often relying on specialised care and costly procedures. By bringing this advanced test into routine care, we are helping physicians to support patients and families with an earlier assessment that is critical for timely intervention, while reducing pressure on healthcare systems."
Collaboration With Lilly Underpins the Assay Development
Elecsys® pTau217 was developed in collaboration with Eli Lilly and Company, reflecting a shared commercial interest in expanding access to Alzheimer's diagnostics as the treatment landscape for the disease develops. Early and accurate diagnosis is a prerequisite for appropriate patient selection in emerging therapeutic programs targeting amyloid pathology.
"For millions of families navigating the uncertainty of Alzheimer's, a timely diagnosis is the first and most critical step toward meaningful care. Lilly's collaboration with Roche on the Elecsys pTau217 assay was driven by a shared commitment to bringing this innovation into routine practice, overcoming complexity in testing and enabling patients to make informed decisions about the future."
For health systems and payers, the diagnostic-therapeutic alignment matters. As amyloid-targeting therapies move through regulatory review and clinical adoption, the availability of a scalable, minimally invasive amyloid detection tool becomes a healthcare system infrastructure requirement, not only a clinical convenience.
Roche's Broader Alzheimer's Diagnostic and Pharmaceutical Portfolio
Elecsys® pTau217 sits within a broader Roche Alzheimer's portfolio that spans multiple biomarker modalities and disease stages. Alongside pTau217, Roche offers blood-based assays for pTau181 and ApoE4, as well as CSF assays and digital solutions, giving laboratory and clinical operators a multi-marker toolkit for disease detection, staging and monitoring.
On the pharmaceutical side, Roche is investigating trontinemab - a Brainshuttle bispecific monoclonal antibody targeting amyloid-beta - in two Phase 3 clinical studies in early Alzheimer's disease. Nivegacetor, an oral gamma-secretase modulator designed to prevent amyloid accumulation, is currently in Phase 2 development. These programs reflect Roche's positioning across the full Alzheimer's care pathway, from early biomarker detection through to potential therapeutic intervention.
Implementation Pathway and US Market Outlook
Following CE Mark clearance, Elecsys® pTau217 will be deployed through Roche's installed instrument base across CE mark-accepting countries. The scale of that installed base is a significant commercial advantage - laboratories in those markets can implement the test within existing workflows without additional capital investment in diagnostic platforms.
Expansion to the United States is subject to FDA approval, which Roche has indicated is under consideration for later this year. The US market represents a substantial opportunity given current diagnostic gaps in primary care Alzheimer's assessment, and the outcome of the FDA review will be closely monitored by health systems, payers and clinical operators in that market.